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Letter to the EditorCharcot-Leyden crystals promote
neutrophilic inflammation
in patients with nasal polyposisTo the Editor:
Since their discovery, Charcot-Leyden crystals (CLCs) have
been considered merely a degradation product and marker of
eosinophilic inflammation.1 CLCs are composed of galectin-10
(Gal10), a protein produced by eosinophils, basophils, and some
T cells that autocrystalizeswhen eosinophils are intensely activated
and undergo cytolysis associated with extrusion of DNA
extracellular traps, a process referred to as EETosis.2,3 CLCs are
abundantly present in mucosa and mucus from patients with
chronic rhinosinusitis with nasal polyps (CRSwNP). Recent work
provided evidence that CLCs, by analogy to other crystals, such
as uric acid and cholesterol crystals, can activate the NLR family
pyrin domain containing 3 (NLRP3) inflammasome and cause
IL-1b–driven inflammation after uptake by human macrophages
in vitro.4 In addition, we have shown that CLCs can stimulate
innate and adaptive immunity and act as a type 2 adjuvant,
promoting key features of asthma in an NLRP3-independent
manner in a mouse model.2
To date, direct effector functions of CLCs on human airway
samples have not been reported. In this study we sought to
investigatewhether and howCLCs activated patient-derived nasal
polyp tissues, isolated airway epithelial cells, and peripheral
blood leukocytes. Details of the materials and methods used in
this study are shown in theMethods section in this article’s Online
Repository at www.jacionline.org.
The process of eosinophil extracellular trap cell death (EE-
Tosis) preferentially occurs at epithelial barrier defects in the
mucosa and mucus of patients with CRSwNP.2,5 Recently, EETo-
sis was shown to be at the basis of CLC formation.2,3 Inspection of
tissue from patients with CRSwNP with a type 2 and IL-5–high
profile showed that CLCs were often lining the epithelial layer
in zones with denuded or abnormal epithelium.2,3 In line with
these observations, we found that CLCs correlated negatively
(P < .001, R 5 20.8792, n 5 12; Fig 1, A) with the relative per-
centage of normal pseudostratified epithelium in polyp tissue
from patients with CRSwNP.
To address the question of whether CLCs could directly cause
epithelial damage, we incubated nasal epithelial cell monolayers
with CLCs grown from recombinant Gal10 and a soluble
crystallization-resistant galectin-10 mutein (Gal10mut) carrying
a Tyr69Glu point mutation.2 A 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay showed a small but
significant decrease in the metabolic activity of primary epithelial
cells after 24 hours of incubation with CLCs (P < .05, n 5 6;
Fig 1, B). However, passive leakage of lactate dehydrogenase
(LDH) was not detected in the supernatant, suggesting that
CLCs interacted with epithelial cells and that cell injury was
minimal after 24 hours.
In mouse models lung administration of CLCs results in influx
of neutrophils into the airway lumen.2,4 In line with these
observations, we measured a significantly increased migration
(P < .05; Fig 1, C) of neutrophils to CLC-stimulated epithelial
cells using a modified Boyden chamber assay, demonstratingthat CLCs stimulate epithelial cells to cause neutrophil
recruitment.
Next, we investigated whether CLCs induced chemokine or
cytokine responses that could activate neutrophils or other
inflammatory cells. Nasal polyp tissue fragments that were
stimulated with 100 mg/mL recombinant CLCs and soluble
Gal10mut (see Fig E1 in this article’s Online Repository at
www.jacionline.org) released significantly increased amounts of
IL-1b (P < .05; see Fig E1, A), IL-1a (P < .05; see Fig E1, B),
TNF-a (P < .05; see Fig E1, C), IL-6 (P < .05; see Fig E1, D),
and IL-8 (P < .05; see Fig E1, E) when measured 24 hours later
and compared with soluble Gal10mut and normal saline control
values. The observed cytokine release in the supernatant
was dependent on the CLC concentration that was applied (see
Fig E2 this article’s Online Repository at www.jacionline.org).
Concentrations of IL-5, IFN-g, and IL-17 were unaltered after
stimulation with either CLCs or Gal10mut compared with control
values (see Fig E3 this article’s Online Repository at
www.jacionline.org). In addition, we found that treatment of
primary epithelial monolayers with recombinant CLCs and
Gal10mut (Fig 1) for 24 hours resulted in a significant increase
in IL-1a (P < .05; Fig 1, E), TNF-a (P < .05; Fig 1, F),
GM-CSF (P < .01; Fig 1, G), and IL-6 (P < .05; Fig 1, H) levels
and a nonsignificant increase in IL-1b (Fig 1, A) and IL-8
(Fig 1, I) levels. Levels of secreted thymic stromal lymphopoietin,
IL-33, and IL-25 were less than the detection limit for all
conditions (data not shown).
Because CLCs triggered epithelial cells to recruit neutrophils
and produce neutrophil-activating cytokines, such as GM-CSF,
TNF-a, and IL-1, that could potentially prime neutrophil effector
function, wemeasured the effects of CLCs on neutrophil function.
An important aspect of neutrophil effector function is extrusion of
DNA in the form of neutrophil extracellular traps (NETs) that are
rich in DNA covered with citrullinated histones.6 Peripheral
blood neutrophils were first primed with GM-CSF and subse-
quently stimulated with CLCs or soluble Gal10mut. Stimulation
with CLCs evoked NET formation, which resulted in a signifi-
cantly increased percentage of neutrophils undergoing NETosis
(P < .05; Fig 2, A-C) based on DNA staining of the neutrophils
on coverslips. In linewith these observations, the amount of extra-
cellular DNA release measured was significantly greater when
neutrophils were exposed to CLCs compared with vehicle
(P < .0001; Fig 2, D) or soluble Gal10mut (P < .001; Fig 2, D).
Neutrophils were stained for citrullinated H3 (citH3; Fig 2, E)
and counted to further verify that the observed DNAwas the result
of induced neutrophil extracellular trap cell death (NETosis). The
number of citH31 neutrophils was significantly increased after
stimulation with CLCs (P < .05; Fig 2, F). Remarkably, no addi-
tive effect of CLCs on NETosis was observed when costimulated
with phorbol 12-myristate 12-acetate (data not shown). The effect
of CLCs on eosinophil EETosis was also studied, and although
stimulation with CLCs after priming showed some induction of
eosinophil extracellular traps (EETs) on coverslips, this effect
was not significant and was not further confirmed by using
DNA quantification in the supernatant (data not shown).
Collectively, these data show that CLCs cause epithelial cells to
recruit neutrophils and produce cytokines that prime neutrophil
function. Subsequently, CLCs steer neutrophils to undergo1
FIG 1. Effects of CLCs on primary nasal epithelial cells.A, Scatter plot of the number of CLCs per high-power
field as a function of percentage of normal pseudostratified epithelium. B, MTT assay after stimulation of
epithelial monolayers for 24 hours with vehicle (normal saline [NS]), soluble Gal10mut (Gal), or CLCs.
C, Boyden chamber assay using peripheral neutrophils toward epithelial cells treated for 24 hours with
vehicle (epithelial cells [EC]), Gal10mut (EC 1 Gal10mut), or CLCs (EC 1 CLC). D-I, Released IL-1b
(Fig 1, D), IL-1a (Fig 1, E), TNF-a (Fig 1, F), GM-CSF (Fig 1, G), IL-6 (Fig 1, H), and IL-8 (Fig 1, I) levels after
24 hours of stimulation with vehicle (normal saline [NS]), 100 mg/mL soluble Gal10mut (Gal10mut), or
100 mg/mL CLCs. Data are normalized as fold induction with respect to cells treated with vehicle. *P < .05
and **P < .01.
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response to CLCs, epithelial cells from nasal polyp tissue, as well
as isolated nasal epithelial cells, produced GM-CSF, a known
priming stimulus for neutrophils. Strikingly, other cytokines that
prime neutrophils for crystal-induced NETosis, such as IL-1a and
TNF-a, were also found to be produced by polyp tissue and
epithelium under these conditions.7 The precise mechanisms by
which CLCs trigger NETosis require further study. Potentially,
the size of the crystals and inability of the crystals to be
phagocytized by neutrophils might be involved in turning onNETosis through reactive oxygen species–dependent transloca-
tion of neutrophil elastase to the nucleus, a mechanism proposed
for sensing of large extracellular pathogens.8 The observed
interindividual variation in response indicates that the role of
CLCs in the pathophysiology of CRSwNP might be valid in
only a specific subtype of CRSwNP. No information is currently
available on how the applied CLC concentration in the in vitro
experiments relates to the concentration in the patient, and
therefore patient-intrinsic dose-response sensitivity might also
emerge in the future.
FIG 2. CLCs cause NETosis. A and B, Immunofluorescent image for DNA (blue) of stimulated neutrophils
with Gal10mut (Fig 2, A) or CLCs (Fig 2, B), indicating formation of NETs (arrowheads) after treatment
with CLCs (Fig 2, B). Scale bar 5 25 mm. C, Relative number of neutrophils involved in NET formation after
primingwith GM-CSF and followed by stimulationwith vehicle (GM-CSF), Gal10mut (GM-CSF1Gal10mut),
and CLCs (GM-CSF 1 CLC). D, Released DNA in supernatants of neutrophils stimulated with vehicle
(GM-CSF), Gal10mut (GM-CSF 1 Gal10mut), and CLCs (GM-CSF 1 CLC). Values are presented as mean
fluorescence intensity (MFI). E, Immunofluorescent image for citH3 (green) and DNA (blue) of peripheral
blood neutrophils after stimulation with CLCs. Scale bar5 25 mm. F, Quantification of the number of citH31
neutrophils after stimulation.
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effectors in patients with CRSwNP, sustaining chronic neutrophilic
inflammation and eventually resulting in NETosis. We suggest that
neutrophils driven by large numbers of CLCs found in the mucosaand mucus of patients with CRSwNP contribute to the persistence
of severe airway disease and might render the inflammation
nonresponsive to current therapeutic possibilities. Appropriate
studies will be required to substantiate this hypothesis.
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METHODS
Patient characterization
The study was approved by the local ethics committee and the regulatory
authorities of Belgium. Written informed consent was obtained from all
subjects before enrollment in the study. Nasal polyp tissue from patients
undergoing endoscopic sinus surgery for CRSwNP were collected. Only
patients with CRSwNPwith a pronounced type 2 inflammation and tissue IL-5
levels of greater than 60 pg/mLwere included in the study. Tissues were either
used immediately, snap-frozen, and/or embedded in paraffin. Peripheral blood
neutrophils were collected from whole blood of healthy volunteers. Exclusion
criteria were pregnancy, lactation, or receipt of intranasal, oral, and/or
intramuscular corticosteroids within the 4 weeks before surgery.
Cytokine and protein measurements
Snap-frozen tissues were weighed, homogenized, and centrifuged, as
described previously.E1 Samples were assayed for IL-5, IL-4, IL-6, IL-8,
IL-1b, IL-17, IFN-g, GM-CSF, and TNF-a by using commercially available
Fluorokine kits from R&D Systems (Minneapolis, Minn) and measured on a
Bio-Plex 200 Array Reader (Bio-Rad Laboratories, Hercules, Calif).
Immunofluorescent staining
Tissues were fixed in 4% paraformaldehyde and embedded in paraffin.
After rehydration of tissue slides (5 mm) and blocking, the slides were
incubated with a polyclonal goat anti-human Gal10 antibody (1:200; Abcam,
Cambridge, Mass), followed by a fluorescein isothiocyanate-conjugated
secondary antibody (1:400). The slides were mounted with Vectashield
containing 49-6-diamidino-2-phenylindole dihydrochloride (Vector Labora-
tories, Burlingame, Calif) and analyzed with a confocal laser-scanning
microscope (Leica Microsystems, Wetzlar, Germany). For each patient and
each piece of tissue, 5 fields were selected in the studied regions, and the
number of CLCs was counted.
For coverslip staining, a similar procedure was used, except for the
paraffin-embedding and rehydration steps. A rabbit anti-human histone H3
(citrulline R2 1 R8 1 R17; 1:200; Abcam) was used as a primary antibody,
followed by a fluorescein isothiocyanante–labeled donkey anti-rabbit
antibody (1:400; Life Technologies, Grand Island, NY).
Stimulation of tissue fragments and epithelial
monolayers
Recombinant Gal10mut, a crystallization-deficient Gal10 carrying a Tyr69-
Glu point mutation, and CLCs were obtained, as described previously.E2 Fresh
tissue (20 mg per stimulation) was stimulated with 10, 50, and 100 mg/mL
Gal10mut or CLCs in RPMI (Life Technologies) supplemented with
100 U/mL penicillin and 100 mg/mL streptomycin (Life Technologies) and
0.1%BSA (Sigma, St Louis, Mo). After 24 hours, the supernatant was collected
by means of centrifugation and stored at2208C until further measurement.
Epithelial cells from patients with CRSwNPwere collected and cultured, as
described previously.E3 At passage 3, the cells were seeded in 24-well plates at
50,000 cells/well. After 48 hours, cells were stimulated with 100 mg/mL
Gal10mut, CLCs, or PBS in complete Bronchial Epithelial Growth Medium
(Lonza, Basel, Switzerland). After 24 hours of stimulation, the supernatant
was collected and stored at 2208C until further measurement. Cells were
washed twice with PBS and used for PCR or Western blotting, as described
elsewhere in this article.
Cytotoxicity measurements
Epithelial cells were stimulated, as described previously. After 24 hours,
the cells were washed twice with PBS and incubated with complete BEGM
containing 5 mg/mL MTT (Sigma-Aldrich) for 4 hours. Then cells were
washed twice and subsequently lysed in dimethyl sulfoxide (Sigma). Ly
absorbance was measured at 570 nm.
For the LDH assay (Sigma), the cells were stimulated, as descr
previously. After 24 hours, the supernatant was analyzed for LDH activit
using an LDH activity kit (Sigma), according to themanufacturer’s instruct
Boyden chamber assay
Three days before the experiment, primary epithelial cells, isolated
cultured as described previously, were seeded at 50,000 cells/well in BE
medium (Lonza) in the basolateral compartment. Twenty-four hours be
the assay, the cells were stimulated with 100 mg/mL Gal10mut, CLCs, or
(vehicle).
For the migration assay, blood neutrophils were collected
whole-blood Ficoll-Paque centrifugation from healthy donors, followe
red blood cell lysis. Subsequently, neutrophils were primed for 20 min
with 100 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ) and then allowe
migrate through 5-mm pore size poly-(vinylpyrrolidone)-free polycarbo
filters (VWR International, Radnor, Pa) for 90 minutes at 378C to the lo
compartment. After the migration assay, migrated cells were collected
subjected to May-Gr€unwald-Giemsa staining and evaluated for the numb
migrated neutrophils.
NET quantification
Blood-derived neutrophils were seeded at a density of 250,000 cells
coverslip (diameter, 13 mm) in X-VIVOmedium (Lonza). Subsequently,
were primed with 100 ng/mL GM-CSF for 20 minutes and subseque
stimulatedwith vehicle (PBS), 100mg/mLGal10mut, or CLCs for 20min
After stimulation, cells were fixed in 10% formalin and stored at 48C in
until further processing. For quantification of NETs based on DNA, cover
were mounted with Vectashield containing 49-6-diamidino-2-phenylin
dihydrochloride (Vector Laboratories). For quantification of cit
neutrophils, coverslips were subjected to an immunofluorescent stain
described previously.
Neutrophils were primed and stimulated with CLCs, as described abov
quantify the amount of released DNA. After stimulation, cells were treate
10 minutes with DNAse (Worthington Biochemical, Lakewood, NJ),
reactionwas stopped by adding EDTA (Life Technologies), and the superna
was collected. The supernatant was measured with the QuantiGene PicoG
Kit (Life Technologies), according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 7 softw
(GraphPad Software, La Jolla, Calif). For between-group comparisons
Mann-WhitneyU test was used. For multiple-group comparisons of unrel
samples, a Kruskal Wallis-test was used, followed by a Dunn mul
comparison test. For related samples, data were analyzed with a Fried
test, followed by a Dunn multiple comparison test. Correlations w
determined with a Pearson correlation or a Spearman rho correlation
P values of less than or equal to .05 were considered statistically signific
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FIG E1. CLCs evoke a proinflammatory response in nasal polyp tissue.A,Released IL-1b levels after 24 hours
of stimulation with vehicle (normal saline [NS]), 100 mg/mL soluble Gal10mut (Gal10mut), or 100 mg/mL
CLCs. B, Released IL-1a levels after 24 hours of stimulation with vehicle (NS), 100 mg/mL soluble Gal10mut
(Gal10mut), or 100 mg/mL CLCs. C, Released TNF-a levels after 24 hours of stimulation with vehicle (NS),
100 mg/mL soluble Gal10mut, or 100 mg/mL CLCs. D, Released IL-6 levels after 24 hours of stimulation
with vehicle (NS), 100 mg/mL soluble Gal10mut (Gal10mut), or 100 mg/mL CLCs. E, Released IL-8 levels after
24 hours of stimulation with vehicle (NS), 100 mg/mL soluble Gal10mut (Gal), or 100 mg/mL CLCs. *P < .05.
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FIG E2. Dose-response curve of the release of cytokines in the function of Gal10mut and CLCs in nasal polyp
tissue fragments. Data are presented as means 6 SEMs.
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FIG E3. Cytokine release in nasal polyp tissue after stimulation. A, Released IL-5 levels after 24 hours of
stimulation with vehicle (normal saline [NS]), 100 mg/mL soluble Gal10mut (Gal10mut), or 100 mg/mL
CLCs. B, Released IFN-g levels after 24 hours of stimulation with vehicle (NS), 100 mg/mL soluble Gal10mut
(Gal10mut), or 100 mg/mL CLCs. C, Released IL-17 levels after 24 hours of stimulation with vehicle (NS),
100 mg/mL soluble Gal10mut, or 100 mg/mL CLCs.
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Highly stable Charcot-Leyden crystals in nasal polyp tissue are deposited by eosinophils undergoing EETosis and actively promote an inﬂammatory
response that sustains chronic neutrophilic inﬂammation.
